Literature DB >> 25595637

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.

Claire M Tully1, Teresa Lambe2, Sarah C Gilbert2, Adrian V S Hill2.   

Abstract

The epidemic of Ebola virus disease has spread at an alarming rate despite containment efforts. As a result, unprecedented large-scale international response efforts have been made in an attempt to gain control of the outbreak and reduce transmission. Several international consortia have been formed in a remarkable worldwide collaborative effort to expedite trials of two candidate Ebola virus vaccines: cAd3-EBOZ and rVSV-EBOV. In parallel, both vaccines are being manufactured in large amounts to enable future rapid deployment for management of the crisis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25595637     DOI： 10.1016/S1473-3099(14)71071-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


  17 in total

1.  Evaluating Ebola vaccine trials: insights from simulation.

Authors:  Juliet R C Pulliam; Steve E Bellan; Manoj Gambhir; Lauren Ancel Meyers; Jonathan Dushoff
Journal:  Lancet Infect Dis       Date:  2015-09-20       Impact factor: 25.071

2.  A vaccine against Ebola: Problems and opportunities.

Authors:  Giovanni Rezza
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Authors:  Gary Wong; Emelissa J Mendoza; Francis A Plummer; George F Gao; Gary P Kobinger; Xiangguo Qiu
Journal:  Expert Opin Biol Ther       Date:  2017-11-17       Impact factor: 4.388

4.  Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks.

Authors:  Lee Kennedy-Shaffer; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2020-11-02       Impact factor: 4.897

5.  Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.

Authors:  Scott A Halperin; Jose R Arribas; Richard Rupp; Charles P Andrews; Laurence Chu; Rituparna Das; Jakub K Simon; Matthew T Onorato; Kenneth Liu; Jason Martin; Frans A Helmond
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

6.  Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.

Authors:  Carole A Federico; Patrick J Heagerty; John Lantos; Pearl O'Rourke; Vasiliki Rahimzadeh; Jeremy Sugarman; Kevin Weinfurt; David Wendler; Benjamin S Wilfond; David Magnus
Journal:  Contemp Clin Trials       Date:  2022-02-15       Impact factor: 2.261

Review 7.  Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Authors:  Vincent Madelain; Thi Huyen Tram Nguyen; Anaelle Olivo; Xavier de Lamballerie; Jérémie Guedj; Anne-Marie Taburet; France Mentré
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

8.  The Ebola Outbreak of 2014-2015: From Coordinated Multilateral Action to Effective Disease Containment, Vaccine Development, and Beyond.

Authors:  Thomas R Wojda; Pamela L Valenza; Kristine Cornejo; Thomas McGinley; Sagar C Galwankar; Dhanashree Kelkar; Richard P Sharpe; Thomas J Papadimos; Stanislaw P Stawicki
Journal:  J Glob Infect Dis       Date:  2015 Oct-Dec

9.  Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak.

Authors:  Mark D Kieh; Elim M Cho; Ian A Myles
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

10.  How can health systems be strengthened to control and prevent an Ebola outbreak? A narrative review.

Authors:  Krishna Regmi; Ruth Gilbert; Colin Thunhurst
Journal:  Infect Ecol Epidemiol       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.